Reveal Lasers LLC, a subsidiary of Reveal Lasers LTD, has recently completed a strategic merger with NEOconcepts LLC, resulting in the acquisition of the AgeJET Advanced Plasma Skin Therapy device. This milestone marks an important step for Reveal Lasers LLC as it expands its presence in the rapidly growing market of plasma skin resurfacing.   Renowned for its cutting-edge technology and exc..
Inogen Expands Its Respiratory Product Portfolio with Acquisition of Physio-Assist   In a move to become a global leader in respiratory care, Inogen, Inc. has announced its acquisition of Physio-Assist SAS. This strategic acquisition allows Inogen to broaden its product offerings and tap into the growing and underserved airway clearance market.   Furthermore, Inogen has provided a prelim..
">With the acquisition of BENEV, ExoCoBio solidifies its position as a global leader in exosome-based regenerative aesthetics. This strategic partnership allows ExoCoBio to further expand the commercialization of exosome technology on a global scale. BENEV, a renowned medical aesthetic brand established in 2000, has been at the forefront of the industry. Their groundbreaking growth factor-based ..
Merck has finalized its acquisition of Prometheus Biosciences for $10.8 billion, gaining five candidates for inflammatory bowel and immune-mediated diseases, including the leading candidate MK-7240 for ulcerative colitis and Crohn's disease. The purchase marks Merck's further expansion into the immunology space. The all-cash agreement includes buying all outstanding shares of Prometheus at a 75%..
Merck & Co has acquired Prometheus Biosciences, Inc. for $10.8 billion, making it a wholly-owned subsidiary and helping Merck expand its presence in immunology while strengthening its pipeline with a potential best-in-class candidate for immune-mediated diseases such as ulcerative colitis and Crohn’s disease. The leading clinical candidate, PRA-023, is now known as MK-7240 and is a humanized mon..
Coherus Biosciences has announced its acquisition of Surface Oncology for up to $65m, which is expected to close in Q3 2023. The deal will see Surface shareholders receive Coherus Biosciences stock as consideration. This move is significant for Coherus, which is launching biosimilar Yusimry in July and currently markets biosimilars of Neulasta and Lucentis. The acquisition will provide Coherus a..
Swiss pharmaceutical company Novartis has announced its acquisition of kidney player Chinook Therapeutics for $3.5 billion, in a bid to expand its renal drug portfolio. The deal includes an upfront cash payment of $3.2 billion and up to $300 million in contingent value rights, payable once certain regulatory milestones are achieved. The acquisition will give Novartis access to Chinook's two late..
TPG Ventures and AmerisourceBergen Corporation have completed their acquisition of OneOncology, a network of leading oncology practices. TPG has acquired a majority interest in OneOncology with AmerisourceBergen acquiring a minority interest. The partnership will provide additional resources to OneOncology, which will allow the company to grow its platform and invest behind clinical, operational..
Medical Technology Associates (MTA) has announced its acquisition of Premier Medical, a Tennessee-based medical gas services and equipment company. The acquisition expands MTA's national presence into Arkansas and Tennessee while strengthening its market-leading position in Florida. Founded in 2000 by Christian Rife, Premier is known for its high-quality employees and marquis customer base. Brin..
